Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a

被引:234
作者
Zeuzem, S
Herrmann, E
Lee, JH
Fricke, J
Neumann, AU
Modi, M
Colucci, G
Roth, WK
机构
[1] Univ Frankfurt Klinikum, Zentrum Inneren Med, Med Klin 2, D-60590 Frankfurt, Germany
[2] Tech Univ Darmstadt, Dept Math, D-64287 Darmstadt, Germany
[3] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel
[4] Hoffmann La Roche, Nutley, NJ USA
[5] Hoffman La Roche, Rotkreuz, Switzerland
[6] Inst Transfus Med & Immunhamatol Blutspendedienst, Frankfurt, Germany
关键词
D O I
10.1053/gast.2001.24006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Backgound & Aims: Covalent attachment of a 40-kilodalton polyethylene glycol moiety to interferon (alpha 2a (peginterferon alpha 2a) results in sustained delivery and reduced clearance compared with standard interferon alpha 2a. The aim of the study was to compare viral kinetics in patients treated with standard or peginterferon (alpha 2a, Methods: Patients with chronic hepatitis C were randomly assigned to receive either standard interferon alpha 2a thrice weekly(n = 16) or 180 mug peginterferon alpha 2a once weekly (n = 17) for 48 weeks, HCV RNA was quantitated before and frequently during treatment. Results: The extent of the second-phase decline of HCV RNA, representing the degradation rate of infected cells during therapy for responding patients, was 0.02 +/- 0.03 day(-1)(HCV-1), 0.88 +/- 0.64 day(-1)(HCV non-1), 0.06 +/- 0.08 day(-1)(HCV-1), and 0.44 +/- 0.33 day(-1) (HCV non-1) in patients treated with standard or peginterferon alpha 2a, respectively. The second-phase decline was low (<0.05 day(-1)) in most patients without a virological end-of-treatment response, and the second-phase decline was high (>0.25 day(-1)) in all patients with sustained virological response. Conclusions: The degradation rate of infected cells is HCV genotype dependent. Treatment with peginterferon alpha 2a may reinforce the death rate of infected cells (particularly in HCV-1-infected patients) or stabilize the therapeutic effect on viral production. The second-phase decline of HCV RNA is predictive of virological sustained response.
引用
收藏
页码:1438 / 1447
页数:10
相关论文
共 25 条
  • [1] Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory
    Albadalejo, J
    Alonso, R
    Antinozzi, R
    Bogard, M
    Bourgault, AM
    Colucci, G
    Fenner, T
    Petersen, H
    Sala, E
    Vincelette, J
    Young, C
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (04) : 862 - 865
  • [2] TIME COURSE OF INTERFERON LEVELS, ANTIVIRAL STATE, 2',5'-OLIGOADENYLATE SYNTHETASE AND SIDE-EFFECTS IN HEALTHY-MEN
    BAROUKI, FM
    WITTER, FR
    GRIFFIN, DE
    NADLER, PI
    WOODS, A
    WOOD, DL
    LIETMAN, PS
    [J]. JOURNAL OF INTERFERON RESEARCH, 1987, 7 (01): : 29 - 39
  • [3] DiDomenico N, 1996, CLIN CHEM, V42, P1915
  • [4] Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant
    Doglio, A
    Laffont, C
    Caroli-Bosc, FX
    Rochet, P
    Lefebvre, JC
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (05) : 1567 - 1569
  • [5] HALGRANATI NE, 1999, HEPATOLOGY S, V30, pA190
  • [6] Herrmann E, 2000, ANTIVIR THER, V5, P85
  • [7] Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management
    Jungkind, D
    DiRenzo, S
    Beavis, KG
    Silverman, NS
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (11) : 2778 - 2783
  • [8] Lam NP, 1997, HEPATOLOGY, V26, P226
  • [9] Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays
    Lee, JH
    Roth, WK
    Zeuzem, S
    [J]. JOURNAL OF HEPATOLOGY, 1997, 26 (05) : 1001 - 1009
  • [10] Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
    Marcellin, P
    Boyer, N
    Gervais, A
    Martinot, M
    Pouteau, M
    Castelnau, C
    Kilani, A
    Areias, J
    Auperin, A
    Benhamou, JP
    Degott, C
    Erlinger, S
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 875 - +